Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company’s subsidiary Algernon Neuroscience has completed dosing of the second cohort in the Phase 1 clinical study of DMT.
Moreau tells Proactive the study is to identify the safety and tolerability of DMT when administered as an intravenous bolus followed by a prolonged infusion of 6 hours which has never been studied clinically.
Proactive Investors
+1 604-688-8158
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.04 |
| Daily Change: | -0.003 -7.32 |
| Daily Volume: | 344 |
| Market Cap: | US$1.040M |
July 16, 2024 April 01, 2024 January 11, 2024 | |
Leveraging its vertically-integrated approach from mine to material manufacturing, Graphite One intends to produce high-grade anode material for the lithium-ion electric vehicle battery market and energy storage systems...
CLICK TO LEARN MORE
UGE International develops, owns, and operates commercial and community solar projects in the United States and strategic markets abroad. Our distributed energy solutions deliver cheaper, cleaner energy to businesses and consumers...
CLICK TO LEARN MORE
